Pilots Fear Retaliation for Refusing Middle East Flights Amid Ongoing Conflict 
Rio Tinto's California Boron Assets Attract Over a Dozen Bidders, Valued at Up to $2 Billion 
Chalco Stock Surges as Q1 2025 Profit Forecast Jumps Up to 58% 
Bendigo and Adelaide Bank Posts Strong Q3 Earnings, Announces AI-Driven Job Cuts 
Chinese Brands Are Taking Over Brazil — And It's Just Getting Started 
BHP's Incoming CEO Visits China Amid Pricing Dispute with CMRG 
Goldman Sachs, ANZ Cut Oil Forecasts Amid U.S.-Iran Ceasefire Hopes 
Meta Is Building an AI Version of Mark Zuckerberg to Interact With Employees 
Kia Cuts EV Sales Target for 2030 Amid Slowing Demand and U.S. Policy Shifts 
San Francisco Suspect Arrested After Molotov Cocktail Attack on OpenAI CEO Sam Altman's Home 
Baker Hughes Sells Waygate Technologies to Hexagon for $1.45 Billion 
Abbott Laboratories Ordered to Pay $53 Million in Premature Infant Formula Lawsuit 
Jefferies Upgrades Starbucks to Hold as China JV Deal Closes and U.S. Business Shows Signs of Recovery 
Bill Ackman Eyes New Fund to Bet Against Market Complacency 
China's AI Stocks Surge as Zhipu and MiniMax Hit Record Highs 
Chinese Cars in Europe: Consumer Trust Is Shifting Fast 
SanDisk Joins Nasdaq-100, Replacing Atlassian on April 20 
SOUTH SAN FRANCISCO, Calif., April 08, 2016 -- Calithera Biosciences, Inc. (Nasdaq:CALA), a clinical-stage pharmaceutical company focused on discovering and developing novel small molecule drugs directed against tumor metabolism and tumor immunology targets for the treatment of cancer, today announced its participation at the 15th Annual Needham Healthcare Conference. William D. Waddill, Senior Vice President and Chief Financial Officer will present on Tuesday, April 12, 2016 at 3:00 p.m. Eastern Time at The Westin New York Grand Central Hotel in New York, NY.
About Calithera
Calithera Biosciences, Inc. is a clinical-stage pharmaceutical company focused on discovering and developing novel small molecule drugs directed against tumor metabolism and tumor immunology targets for the treatment of cancer. Calithera’s lead product candidate, CB-839, is currently being evaluated in three Phase 1 clinical trials in solid and hematological cancers. CB-1158 is a first-in- class immuno-oncology metabolic checkpoint inhibitor targeting arginase, a critical immunosuppressive enzyme responsible for T-cell suppression by myeloid-derived suppressor cells. Arginase depletes arginine, a nutrient that is critical for the activation, growth and survival of the body’s cancer-fighting immune cells, known as cytotoxic T -cells. Calithera is headquartered in South San Francisco, California. For more information about Calithera, please visit www.calithera.com.
Contact: Jennifer McNealey [email protected] 650-870-1071
